![]() This increase was primarily due to increased payroll, stock-based compensation, insurance, and professional service expenses. G&A Expenses: General and administrative expenses were $8.2 million for the quarter ended June 30, 2022, as compared to $7.0 million for the quarter ended June 30, 2021. This increase was primarily driven by the progression of our five existing clinical product candidates, including 4D-150 (for wet AMD), 4D-310 (for Fabry disease) and 4D-710 (for cystic fibrosis lung disease). R&D Expenses: Research and development expenses were $20.4 million for the quarter ended June 30, 2022, as compared to $15.2 million for the quarter ended June 30, 2021. Revenue: Total revenue for the quarter ended June 30, 2022, was $0.2 million, as compared to $14.6 million for the quarter ended June 30, 2021. We expect cash, cash equivalents and marketable securities to be sufficient to fund operations into the first half of 2025. The company continues to expect to provide a clinical data update on 4D-310 in the 1st half of 2023.Ĭash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities were $261.6 million as of June 30, 2022. The inclusion of female patients in the phase 1/2 clinical trial was supported by clinical experience to-date, as well as a GLP toxicology study in female mice. The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease. Food and Drug Administration (FDA) for the ongoing Phase 1/2 clinical trial of 4D-310 for Fabry disease. In June 2022, 4DMT filed a protocol amendment with the U.S. ![]() Update on 4D-310 Phase 1/2 Clinical Trial for Fabry Disease Our team is committed to relentless execution as we make progress toward key clinical data readouts in the first half of 2023 and beyond.” ![]() We have maintained our focus on efficient cash utilization, with current cash available to support our operations into the first half of 2025. “In addition, the protocol amendment for the 4D-310 Phase 1/2 clinical trial in Fabry disease will expand access to include female patients, a large and significantly affected patient population with Fabry disease. "Maintaining our momentum from the first quarter, we continued to execute towards our clinical and corporate milestones, including progress across all of our five clinical-stage product candidates,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, reported second quarter 2022 financial results and provided a 4D-310 program update. 11, 2022 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. 4D-310 Phase 1/2 clinical trial eligible patient population expanded to include females with Fabry diseaseĮMERYVILLE, Calif., Aug. Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 The visa approval numbers from consular processing are provided by Depart of State (DoS) and can be reviewed on website.- Five clinical-stage product candidates on track for multiple clinical data updates in 2023 If you are outside country, then employer will ask the H1B worker to attend visa interview at the nearest consulate. USCIS data is only for folks who are already in the USA and requesting for change of status (COS). USCIS review the H1B applications (new, renewals, and transfer of employer) and can result in approval or denial. Once DOL approves LCA, the petition is submitted to USCIS for review. On the other hand USCIS data indicates, how much success does an employer have in getting the LCAs to hiring those foreign workers. Read more about LCA process in blog article. In other words, filing an LCA and getting an approval is a mandatory step for H1B visa. One LCA application can be used to fulfil many open positions by an employer. These applications are either new employment, continuation of the employment or change of employers. LCA data represents the number of applications filed with Department Of Labor (DOL) request to hire a foreign worker. Below is the charts and tables of Labor Condition Application (LCA) approvals and denials along with USCIS approvals and denials.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |